GlassScriptPhysician profile
Janet L Kwiatkowski
NPI 1093738833
$65,359.60
in general payments reported to CMS, 2019-2025
16 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 75% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,888 · 2021: $8,349 · 2022: $17K · 2023: $11K · 2024: $4,971 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,558 · Honoraria: $8,588 · Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,557.88 |
| Honoraria | $8,587.50 |
| Food and Beverage | $496.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $23,121.43 | 2019-2025 | Pyrukynd |
| Chiesi USA, INC. | $18,045.47 | 2020-2025 | Ferriprox |
| Celgene Corporation | $10,781.02 | 2019-2021 | |
| Novo Nordisk Health Care Ag | $5,000.00 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $4,145.00 | 2022 | |
| Biomarin Pharmaceutical INC. | $2,400.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $1,697.50 | 2023 | |
| Apo-Pharma INC. | $125.00 | 2019 | |
| Genetix Biotherapeutics INC | $23.55 | 2023 | |
| Abbott Laboratories | $20.63 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Kwiatkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.